Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors

Tenalisib (RP6530, selective dual PI3K d/? inhibitor with additional SIK3 inhibitory activity) showed encouraging results with a clinical benefit rate (CBR) of 57.5% from an ongoing phase II trial

Related Keywords

Georgia ,United States ,Paris ,France General ,France ,Poland ,Switzerland ,Swiss ,Samyukta Bhagwati ,Kostenloser Wertpapierhandel ,Swaroop Vakkalanka ,Rhizen Pharmaceuticals ,Rhizen Pharmaceuticals Ag Contact ,Rhizen Pharmaceuticals Ag ,Corporate Affairs Communications ,Clinical Benefit Rate ,Poster Presentation ,Tamta Makharadze ,Piotr Tomczak ,Rhizen ,Pharmaceuticals ,Nnounces ,Pcoming ,Data ,Presentations ,Osmo ,022 ,Linical ,Stage ,Assets ,Enalisib ,Ocally ,Dvanced ,Metastatic ,Breast ,Dancer ,P12146 ,Multiple ,Olid ,Rumors ,